NASDAQ: MNPR

Monopar Therapeutics Inc.

Healthcare | Biotechnology

No licensed closing price on file for MNPR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS$-1.85

Monopar Therapeutics Inc. (NASDAQ: MNPR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 17:52 UTC.

What Monopar Therapeutics Inc. does

The company has obtained intellectual property for ALXN1840 through a license agreement with AstraZeneca, which includes patent applications and grants covering treatment methods and drug formulations for Wilson disease; ALXN1840 has received Orphan Drug Designation and Fast Track status from the FDA. The company also holds patents for MNPR-101 for radiopharmaceutical use, though certain foundational patents for this program are expiring soon. The company protects its intellectual property through patents, trade secrets, and confidentiality agreements with employees and collaborators.

Summarized from Monopar Therapeutics Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation	8-K 2026-06-30
EPS	$-1.85

Charts

Charts are in the appInteractive charts for MNPR are available in Oxford Ledge.
Open MNPR in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-05

2026-10-05DirectorSale-4,631$361.6K
2026-10-05DirectorSale-799$63.7K
2026-10-05DirectorStock OptionOption exercise-8,400—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Jupiter Topco LLC1,312,129$121.70MNEW
JANUS HENDERSON GROUP PLC1,317,410$72.06M0.0%
RA CAPITAL MANAGEMENT, L.P.667,207$61.78M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-03-03Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-05-24Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Monopar Therapeutics: ALXN1840's Bull Case Has Improved
Seeking Alpha Feed2026-07-03
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Monopar Therapeutics Inc. do?

Monopar Therapeutics Inc. is a biotechnology company, listed on NASDAQ as MNPR.

When did MNPR last file with the SEC?

Monopar Therapeutics Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 17:52 UTC. This page is also available as JSON at /api/data?ticker=MNPR and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MNPR and 5,000+ tickers.

Create a free account — keep MNPR

For your agent

GET /api/data?ticker=MNPR

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt